X4 Pharmaceuticals, Inc. (XFOR)
Nasdaq · Healthcare · Biotechnology
$2.90+2.47%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $288M
- P/E (trailing)
- 145.0
- 52-week range
- $2.73 – $4.83
- 52-week change
- −17.73%
- EPS (trailing)
- $0.02
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $6.5M (+150.00%)
- Net income
- −$79.2M
- Operating margin
- −1336.7%
- Diluted EPS
- −$1.87
- Free cash flow
- −$85.6M
From the company’s annual report on SEC EDGAR.
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 45 employees · x4pharma.com